A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to demonstrate that addition of rosiglitazone (4mg) to insulin in Type
2 diabetes mellitus subjects who have not achieved glycemic goals on insulin injections alone
is efficacious in terms of improving glycemic control.